ETFsDeutsche Borse SDAX Performance Index
Amundi
Amundi SDAX UCITS ETF Dist
C005 XETRADistributingPhysical, full replicationLuxembourgNot PEA-eligible
Last close · EUR
138.96EUR
-1.19% · -€1.68
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
C005Base
- Fund charges
- 0.70%Total expense ratio (TER)
- Fund size
- €159.9Mall share classes
- Return 1Y
- +11.2%
- Sharpe 3Y
- 0.53
- Volatility 1Y
- 18.5%annualised
- Holdings
- 71Fund holdings
Performance
Compare
- C005+11.2%
- Price, EUR
Returns
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| C005 | -0.6% | -2.7% | -1.0% | +4.7% | +11.2% | +36.7% | +0.3% |
| MSCI World | -2.8% | -0.6% | +7.8% | +14.0% | +14.1% | +65.6% | +64.8% |
| Gap to MSCI World | +2.2% | -2.1% | -8.9% | -9.3% | -2.9% | -28.9% | -64.6% |
Risk and return
Sharpe ratio · 3Y
0.53
Below MSCI World · 1.24- Return p.a.
- +11.1%
- Volatility
- 17.2%
- Max loss
- -16.9%Apr 2025
Sharpe vs indices
MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
C005
0.53
CAC 40
0.37
Method
Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.
Top holdings
- Top 10
- 28.2%
- Holdings
- 71
- As of
- 1CARL ZEISS MEDITEC AGDE00053137043.25%
- 2BEFESA SALU17046501643.23%
- 3SMA SOLAR TECHNOLOGY AGDE000A0DJ6J93.16%
- 4REDCARE PHARMACY NVNL00120447473.15%
- 5ALZCHEM GROUP AGDE000A41YHG12.69%
- 6JUNGHEINRICH NON VTG PRF DM50DE00062199342.67%
- 7HUGO BOSS AG ORDDE000A1PHFF72.55%
- 8TONIES SE - ALU23335632812.55%
- 9SIXT SEDE00072313262.46%
- 10SAF-HOLLAND SEDE000SAFH0012.45%
Countries
Classified 99.5%
Germany99.5%
- Largest
- 99.5%Germany
- Top 3
- 99.5%
- Effective number
- 1.01 / HHI
Market cap
Weight vs holdings
28.2%of the fund sits in the top 10 holdings
28.2%59.1%12.3%
WeightHoldings
104021
- Holdings 1-10
- Holdings 11-50
- Holdings 51-71
Size split
Not published
Compare ETFs in Copio.
Factual research, without a suitability score or investment recommendation. Past relationships can change.